MedTrace Logo

Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer

NCT06800313 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 190

Last updated 2026-08-20

No results posted yet for this study

Summary

Assessment of the safety and efficacy of HLD-0915 (JNJ-101556143) in patients with metastatic prostate cancer who have progressed on prior systemic therapies, with further evaluation in additional prostate cancer populations.

Conditions

Interventions

DRUG

JNJ-101556143 Formulation 1

Experimental: Oral JNJ-101556143

DRUG

JNJ-101556143 Formulation 2

Experimental: Oral JNJ-101556143

DRUG

JNJ-101556143 Formulation 3

Experimental: Oral JNJ-101556143

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    lead INDUSTRY

Principal Investigators

  • Janssen Research & Development, LLC Clinical Trial · Janssen Research & Development, LLC

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-06
Primary Completion
2028-07-11
Completion
2028-07-11
FDA Drug
Yes

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06800313 on ClinicalTrials.gov